Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
BioNTech SE
ImmunityBio, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
National Cancer Institute (NCI)